OR WAIT null SECS
September 16, 2019
The acquisition will enhance Lundbeck’s brain disease therapy portfolio as well as its antibody process and development capabilities.
The acquisition gives PPF a 19.2% stake in Autolus and provides a pipeline of cell therapy product candidates.
Nephron Pharma and the University of South Carolina plan to build a sterile compounding lab at the University for research and training.
September 15, 2019
A GAO report analyzes some of the reasons why so few generics are approved the first time around. NIPTE has proposed a program that would address these issues.
September 13, 2019
TrakCel and McKesson have formed a collaboration that is aimed at accelerating commercialization of cell and gene therapies by leveraging services to enable a more efficient development pathway.
FDA approved the drug after a successful open-label study of children aged six to 11 years and living with the condition.
The companies will develop and commercialize a Phase III cell therapy candidate for treating chronic low back pain in a deal worth potentially $1 billion.
September 09, 2019
The new antibody, Citryll’s CIT-013, could offer new treatment options for various human diseases including lupus, vasculitis, pulmonary fibrosis, and organ damage due to sepsis.
September 04, 2019
In a Phase III trial for advanced small-cell lung cancer, the investigational antibody drug conjugate, Rova-T (rovalpituzumab tesirine), did not demonstrate a survival benefit for patients taking it.
The company has received breakthrough therapy designation for its prophylactic respiratory syncytial virus vaccine candidate for treating adults aged 60 years or older.
